Dr. Leonidas Stamatatos

powered by
COS Expertise®
Seattle Biomedical Research Institute
Global Health
Affiliate Professor

Mailing Address

307 Westlake Avenue North
Seattle, Washington 98109
United States

Contact Information

Phone: (206) 256-7200
Fax: (206) 256-7229
leo.stamatatos@sbri.org

Qualifications

Ph.D., McGill University, Biochemistry, 1988.

Expertise and Research Interests

A major area of interest for our team is to better understand how neutralizing antibodies against HIV are developed during natural HIV-infection. We are particularly interested in: a) identifying factors influencing the development of such antibodies, b) understanding how the virus evolves to avoid the action of such antibodies, and c) identifying the particular HIV epitopes that these antibodies target

Another major research focus is the comparative evaluation of various approaches to design novel HIV vaccines to elicit neutralizing antibodies against all viral variants circulating in the world.

Keywords

COS Keywords:

Biochemistry, HIV, Immunology, Pathobiology, Pathogenesis, Vaccine, Virology.

Additional Terms:

HIV, Immunology, Pathogenesis, Structure/Function Analysis of HIV Envelope, Transmission, Vaccines, Viruses.

Languages

(Reading, Writing, Speaking)

English
French
Greek

Memberships

American Association for the Advancement of Science
American Society of Microbiology
Faculty 1000 Medicine
International Society for Vaccines

Honors and Awards

1996-1998, Training grant, Pediatric AIDS Foundation, HIV/AIDS
1995-1998, Scholar award, American Foundation for AIDS Research, HIV/AIDS
1984-1986, Graduate Scholl Award, Public Benefit Foundation 'Alexandros Onassis'
2004-2008 Member, NIH

Previous Positions

2001-2008, Associate Professor, University of Washington
1996-2001, Assistant Professor, The Rockefeller University

Funding Received

  • National Institutes of Health (NIH): Design of effective subtype A HIV envelope immunogens, Sep 1, 2003 to Aug 31, 2008.
  • National Institutes of Health (NIH): Vaccine Efficacy of Modified HIV Envelopes, Jun 30, 2000 to 2010.
  • B&MGF: HIV Vaccine Discovery Centers, 2006 to 2011.

Publications

  • Sather, D.N. (2009) Differential pathogenicity of SHIVSF162P4 infection in pig-tailed and rhesus macaques, J. Virology, 83, 757-769
  • L. Ching (2008) The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous HIV-1 isolates to neutralizing antibodies elicited by gp140 immunogens, J. Virology, 82, 949-956
  • Y. Xu (2008) Blood monocytes harbor human immunodeficiency virus type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus, J. Infectious Diseases, 107, 309-318
  • I. Srivastava (2008) Comparative Evaluation of Trimeric Envelope Glycoproteins Derived from Subtype C and B HIV-1 R5 Isolates., Virology, 372, 273-290
  • Kraft, Z (2008) Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses, J. Virology, 82, 5912-5921
  • Z. Kraft (2007) Macaques infected with a CCR5-tropic Simian/Human Immunodeficiency Virus develop broadly reactive anti-HIV neutralizing antibodies, J. Virology, 81, 6402-6411
  • N. R. Derby (2007) Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens, Virology, 366, 433-445
  • Xu, R, Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection, Virology, 349, 276-289, 2005
  • Bolesta, E, Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV Env glycoprotein when combined with IL21 and IL15 gene delivery, Journal of Immunology, 177, 177-191, 2006
  • D. Kozbor (2006) Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV Env glycoprotein when combined with IL21 and IL15 gene delivery, J. Immunol., 177, 177-191
  • N. Derby (2006) Comparative analysis of antibody responses elicited in macaques immunized with HIV-1 SF162-derived gp140 envelope immunogens with those elicited during homologous SHIVSF162 and heterologous HIV-1 infection, J. Virol., 80, 8745-8762
  • 37. Sharma, VA (2006) Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines, Virology, 352, 131-144
  • Xu, R. (2006) Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein, AIDS Research and Human Retroviruses, 22, 1022-1030
  • Burke, B (2006) Viral evolution in macaques co-infected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies, Virology, 355, 138-151
  • Gorny, M.K, Identification of a New Quaternary Neutralizing Epitope on HIV-1 Virus Particles, Journal of Virology, 79, 5232- 5237, 2005
  • Witvrow, M, Resistance of Human Immunodeficiency Virus Type 1 to the High-mannose Binding Agents Cyanovirin N and Concanavalin a, Jounral of Virology, 79, 7777-7784, 2005
  • Saunders, C.J, The V1, V2, and V3 Regions of the HIV-1 Envelope Differentially Affect the Viral Phenotype in An Isolate-dependent Manner, Jounral of Virology, 79, 9069-9080, 2005
  • Li, M, Human Immunodeficiency Virus Type 1 Env Clones From Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-elicited Neutralizing Antibodies, Journal of Virology, 79, 10108-10125, 2005
  • 32. Saunders, C.J, The V1, V2, and V3 regions of the HIV-1 envelope differentially affect the viral phenotype in an isolate-dependent manner, Journal of Virology, 79, 9069-9080, 2005
  • Li, M, Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies, Journal of Virology, 79, 10108-10125, 2005
  • Buckner, C., L. G. Gines, C. J. Saunders, L. Vojtech, I. Srivastava, A. Gettie, R. Bohm, J. Blanchard, S. W. Barnett, J. T. Safrit and L. Stamatatos, Priming of B anti-HIV envelope responses by vaccination is essential for the long lasting containment of viral replication in macaques infected with an R5-tropic SHIV isolate, Virology, 320, 167-180, 2004
  • McCaffrey, A.R., C. Saunders, M. Hensel, and L. Stamatatos, N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies, Journal of Virology, 78, 3279-3295, 2004
  • Haigwood, L. N. and L. Stamatatos, Role of neutralizing antibodies in HIV infectio, AIDS (Year in review), 7 (suppl. 4), S67-S71, 2004
  • McCaffrey, A.R, N-linked Glycosylation of the V3 Loop and the Immunologically Silent Face of Gp120 Protects Human Immunodeficiency Virus Type 1 SF162 From Neutralization By Anti-gp120 and Anti-gp41 Antibodies, 2004
  • Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L, Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region, Journal of Virology, 77(4), 2310-20, February 2003 Abstract
  • Srivastava, I, K., L. Stamatatos, E. Kan, M. Vajdy, Y. Lian, S. Hilt, L. Martin, C. Vita, P. Zhu, K. H. Roux, L. Vojtech, D. Montefiori, J. Donnelly, J. B. Ulmer and S. W. Barnett, Purification, characterization and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 Loop derived from SF162, an R5-tropic primary HIV-1 isolate, Journal of Virology, 77, 11244-11259, 2003
  • Gummuluru, S., M. Rogel, L. Stamatatos, and M. Emerman, Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol dependent pathway, Journal of Virology, 77, 12865-12874, 2003
  • Haigwood, L. N. and L. Stamatatos, Role of neutralizing antibodies in HIV infection, AIDS (Year in review), 17, S67-S71, 2003
  • Srivastava, I. K., L. Stamatatos, A. Fong, H. Legg, E. Kan, S. Coates, L. Leung, M. Wininger, J. Donnelly, J. B. Ulmer and S. W. Barnett., Purifications and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus, Journal of Virology, 76, 2835-284, 2002
  • Cherpelis, S., X. Jin, A. Gettie, D. D. Ho, S. W. Barnett, I. Srivastava and L. Stamatatos, DNA-immunization with a V2 deleted HIV envelope elicits protective antibodies in macaques, Journal of Immunol. Letters, 79, 47-55, 2001
  • Barnett, S. W., S. Lu, I. Srivastava, S. Cherpelis, A. Gettie, J. Blanchard, S. Wang, I. Mboudjeka, L. Leung, Y. Lian, A. Fong, C. Buckner, A. Ly, S. Hilt, J. Ulmer, C. Wild, J. Mascola and L. Stamatatos, The ability of an oligomeric HIV-1 envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following the partial deletion of the second hypervariable region, Journal of Virology, 75, 5526-5540, 2001
  • Cherpelis, S., I. Shrivastava, A. Gettie, X. Jin, D. D. Ho, S. W. Barnett and L. Stamatatos, DNA vaccination with the human immunodeficiency virus type 1 SF162DV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T cell-, Journal of Virology, 75, 1547-1550, 2001
  • Ignatius, R., K. Mahnke, M. Rivera, K. Hong, F. Isdell, R. M. Steinman, M. Pope, and L. Stamatatos, Presentation of proteins encapsulated into sterically-stabilized liposomes by dendritic cells initiates CD8+ T cell responses in vivo, Blood, 96, 3505-3513, 2000
  • Stamatatos, L., M. Lim and C. Cheng-Mayer, Generation and structural analysis of soluble oligomeric envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV-1 isolates, AIDS Research and Human Retroviruses, 16, 981-994, 2000
  • Ly, A and L. Stamatatos, V2 loop-glycosylation of the HIV-1SF162 envelope facilitates the interaction of this protein with the CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4-bin, Journal of Virology, 74, 6769-6776, 2000
  • Stamatatos, L and C. Cheng-Mayer, An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades, Journal of Virology, 72, 7840-7845, 1998
  • Stamatatos, L., M. Wiskerchen, and C. Cheng-Mayer, Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV-1 isolate on viral envelope structure, cell-entry and replication, AIDS Research and Human Retroviruses, 14, 1129-1139, 1998
  • Stamatatos, L., S. Zolla-Pazner, M.K. Gorny, and C. Cheng-Mayer, Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononucle, Virology, 229, 360-369, 1997
  • Cheng-Mayer, C., R. Liu, N.R. Landau, and L. Stamatatos, Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor, Journal of Virology, 71, 1657-1661, 1997
  • Mo, H., L. Stamatatos, J.E. Ip, D.R. Burton, J.P. Moore, and D.D. Ho, Characterization of human immunodeficiency virus type 1 neutralization escape mutants to human monoclonal antibody IgG1b12, Journal of Virology, 71, 6869-6874, 1997
  • Stamatatos L, Cheng-Mayer C, Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying disti, Journal of Virology, 69(10), 6191-8, October 1995 Abstract
  • Koito A, Stamatatos L, Cheng-Mayer C, Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120, Virology, 206(2), 878-84, February 1995 Abstract
  • Stamatatos L, Levy JA, CD26 is not involved in infection of peripheral blood mononuclear cells by HIV-1, Aids (london, England), 8(12), 1727-8, December 1994 Abstract
  • Stamatatos L, Werner A, Cheng-Mayer C, Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1, Journal of Virology, 68(8), 4973-9, August 1994 Abstract
  • Stamatatos L, Cheng-Mayer C, Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability, Journal of Virology, 67(9), 5635-9, September 1993 Abstract
  • Stamatatos L, Duzgunes N, Simian immunodeficiency virus (SIVmac251) membrane lipid mixing with human CD4+ and CD4- cell lines in vitro does not necessarily result in internalization of the viral core proteins and p, Journal of General Virology, 74 ( Pt 6), 1043-54, June 1993 Abstract
  • Duzgunes N, Pedroso de Lima MC, Stamatatos L, Flasher D, Alford D, Friend DS, Nir S, Fusion activity and inactivation of influenza virus: kinetics of low pH-induced fusion with cultured cells, Journal of General Virology, 73 ( Pt 1), 27-37, January 1992 Abstract
  • Konopka K, Stamatatos L, Larsen CE, Davis BR, Duzgunes N, Enhancement of human immunodeficiency virus type 1 infection by cationic liposomes: the role of CD4, serum and liposome-cell interactions, Journal of General Virology, 72 ( Pt 11), 2685-96, November 1991 Abstract
  • Witvrow, M., Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A, Journal of Virology, 79, 7777-7784

Profile Details

Last Verified: 1/9/2009

COS Expertise ID #1083675
Reference this profile directly: http://myprofile.cos.com/jjmasnatalia